Meta analysis on the efficacy of capecitabine in the chemotherapy of metastatic breast cancer

Abstract

Abstract: AIM: In recent years, the conclusion about the efficacy and toxicity of capecitabine in the chemotherapy of metastatic breast cancer was discordant. This Meta analysis was to ascertain the efficacy and toxicity of capecitabine in metastatic or advanced breast cancer.METHODS: By searching the Cochrane, Pubmed, EMbase, Medline, CBM, CNKI, Wanfang databases, randomized controlled trials (RCTs) and quasi-RCTs about chemotherapy with or without capecitabine before March 2014 were included. Date were merged and analysed by RevMan 5.2.RESULTS: Nine RCTs and one quasi-RCT involving 1 449 patients with advanced or metastatic breast cancer were included. Results showed that the chemotherapy which included capecitabine had higher overall survival (OR)(RR=1.61;95%CI:1.29-2.02,P<0.0001), complete survival (CR)(RR=1.68;95%CI:1.04-2.71,P<0.03), gastrointestinal reaction, hand-foot syndrome rate and lower myalgia rate, myelotoxicity rate when compared with chemotherapy without capecitabine.CONCLUSION: This Meta analysis shows that chemotherapy which included capecitabine can increase the OR and CR in the metastatic or advance breast cancer. Correspondingly, people should pay more attention to some of the adverse events such as hand-foot syndrome.

Key words: capecitabine, breast cancer, Meta analysis

CLC Number:

LAN Ke, LI Wen-han, XU Zi-sen, DANG Cheng-xue. Meta analysis on the efficacy of capecitabine in the chemotherapy of metastatic breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 425-429.

References

[1] Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer[J]. Lancet Oncol, 2014, 15(2): e58-e68.
[2] Wang AT, Vachon CM, Brandt KR, et al. Breast density and breast cancer risk: a practical review[J]. Mayo Clin Proc, 2014, 89(4): 548-557.
[3] 朱益平,盛莉莉,路王,等. NX方案和GP方案治疗蒽环类及紫杉类药物治疗后复发转移乳腺癌的临床疗效分析[J]. 中国临床药理学与治疗学, 2013, 9(8): 918-924.
[4] 郝吉庆, 马强, 刘彭坤. 吉西他滨联合洛铂或顺铂治疗蒽环类和紫杉类药物耐药晚期乳腺癌的比较研究[J]. 中国临床药理学与治疗学, 2012, 17(5): 554-558.
[5] Daniele G, Gallo M, Piccirillo MC, et al. Pharmacokinetic evaluation of capecitabine in breast cancer[J]. Expert Opin Drug Metab Toxicol, 2013, 9(2): 225-235.
[6] Bonotto M, Bozza C, Di Loreto C, et al. Making capecitabine targeted therapy for breast cancer: which is the role of thymidine phosphorylase[J]? Clin Breast Cancer, 2013, 13(3): 167-172.
[7] O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results[J]. J Clin Oncol, 2002, 20(12): 2812-2823.
[8] 李明毅,林大任,谭洁媚. 卡培他滨联合多西紫杉醇治疗蒽环类耐药的转移性乳腺癌31例[J]. 中华肿瘤防治杂志, 2006, 8(3): 216-217.
[9] 吴慧娟,刘涛,邹宏志. 多西紫杉醇卡培他滨治疗蒽环类耐药的乳腺癌研究[J]. 医药论坛杂志, 2007, 6(16): 59-60.
[10]Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer[J]. J Clin Oncol, 2010, 28(6): 976-983.
[11]赵韬,邵清,张汀荣,等. 希罗达在转移性乳腺癌维持治疗中的疗效观察[J]. 实用临床医药杂志, 2011, 7(7): 88-90.
[12]张明帅,张国庆,欧江华,等. 唑来磷酸联合卡培他滨治疗乳腺癌多发骨转移临床疗效研究[J]. 中国全科医学, 2011, 8(35): 4103-4105.
[13]Hatschek T, Carlsson L, Einbeigi Z, et al. Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial[J]. Breast Cancer Res Treat, 2012, 131(3): 939-947.
[14]蒋伟丰,汪永旭. 多西他赛联合卡培他滨治疗老年转移乳腺癌的临床观察[J]. 中国高等医学教育, 2012, 10(12): 133-146.
[15]孟秀敏. 多西他赛联合卡培他滨治疗紫杉醇耐药乳腺癌患者40例[J]. 中国药业, 2013, 10(17): 64-65.
[16]王淑芳,牛晓薇. 卡培他滨维持治疗在晚期三阴性乳腺癌治疗中的临床应用[J]. 中国社区医师(医学专业), 2013, 6(5): 138-139.
[17]Wang Y, Yang H, Wei J F, et al. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials[J]. Curr Med Res Opin, 2012, 28(12): 1911-1919.
[18]Mavroudis D, Papakotoulas P, Ardavanis A, et al. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer[J]. Ann Oncol, 2010, 21(1): 48-54.
[19]Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer[J]. J Clin Oncol, 2009, 27(11): 1753-1760.